Pulmatrix (PULM) Research & Development (2013 - 2026)
Pulmatrix (PULM) reported Research & Development of $2,000 for Q2 2026, down 85.7% from $14,000 a year earlier and down 33.3% from the prior quarter.
Powered by 
Analysis
Pulmatrix (PULM) Research & Development (2013 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Pulmatrix's Research & Development came in at $10,000, down 98.8% year-over-year; for FY2025, it was $38,000, down 99.5% from FY2024.
- Research & Development has declined for three consecutive years, with a five-year compound annual growth rate of -70.0% (FY2020 to FY2025).
- By year, Research & Development came in at $7.17 million in FY2024 (-53.8%), $15.52 million in FY2023 (-14.9%), $18.24 million in FY2022 (+18.6%) and $15.38 million in FY2021 (-1.5%).
- Five-year quarterly Research & Development spans a low of -$3,000 in Q4 2025 and a high of $5.29 million in Q3 2022.
- The high point for year-over-year Research & Development in five years was Q4 2022 (growth of 51.0%); the low point was Q4 2024 (a decline of 99.8%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $3,000 (Q1 2026), -$3,000 (Q4 2025) and $8,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Pulmatrix | 5.55 Mn | 5.55 Mn | - | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 814,000.00 |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Sep 30, 2023 | 3.96 Mn |
| Jun 30, 2023 | 4.17 Mn |
| Mar 31, 2023 | 3.87 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 5.29 Mn |
| Jun 30, 2022 | 4.34 Mn |
| Mar 31, 2022 | 4.15 Mn |
| Dec 31, 2021 | 2.96 Mn |
| Sep 30, 2021 | 4.03 Mn |
API Access
Pulmatrix Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=PULM&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "PULM", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=PULM&period=max&api_key=YOUR_API_KEY");
const data = await res.json();